Profusa Submits CE Mark Application for Lumee Oxygen Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: Newsfilter
- CE Mark Progress: Profusa has submitted its response package to GMED for the Lumee Oxygen Platform, marking a significant milestone in the MDR conformity assessment process aimed at obtaining CE Mark certification to support its commercialization strategy in Europe.
- Technical Documentation Updates: The response package includes updates on technical documentation, quality system evidence, and clinical evaluation activities, demonstrating the company's ongoing efforts to meet regulatory requirements, thereby enhancing its competitive position in the market.
- Real-Time Monitoring Capability: The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through its proprietary tissue-integrated biosensor technology, addressing clinicians' needs for objective tissue perfusion data that may improve patient monitoring and treatment decision-making.
- Future Outlook: Although the CE Mark review process is ongoing, Profusa is committed to supporting the review and providing updates on significant regulatory milestones, reflecting its confidence in future product launches and keen insight into market demands.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PFSA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PFSA
About PFSA
Profusa, Inc. is a commercial stage digital health company. The Company is engaged in the development of a new generation of biointegrated sensors that potentially empower the individual with the ability to monitor their body chemistry. The Company’s technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. Its first clinical offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels in various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds (diabetic ulcers, pressure sores) that do not heal properly; and reconstructive surgery.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Profusa Submits CE Mark Application for Lumee Oxygen Platform
- CE Mark Progress: Profusa has submitted its response package to GMED for the Lumee Oxygen Platform, marking a significant milestone in the MDR conformity assessment process aimed at obtaining CE Mark certification to support its commercialization strategy in Europe.
- Technical Documentation Updates: The response package includes updates on technical documentation, quality system evidence, and clinical evaluation activities, demonstrating the company's ongoing efforts to meet regulatory requirements, thereby enhancing its competitive position in the market.
- Real-Time Monitoring Capability: The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through its proprietary tissue-integrated biosensor technology, addressing clinicians' needs for objective tissue perfusion data that may improve patient monitoring and treatment decision-making.
- Future Outlook: Although the CE Mark review process is ongoing, Profusa is committed to supporting the review and providing updates on significant regulatory milestones, reflecting its confidence in future product launches and keen insight into market demands.
See More
Profusa Inc. Lists on Nasdaq Capital Market to Ensure Compliance
- Listing Progress: Profusa Inc. officially lists on the Nasdaq Capital Market as of May 15, 2026, marking a strategic move to comply with the Nasdaq Hearings Panel's requirements for bid price and stockholders' equity to maintain its listing status.
- Technological Innovation: As a digital health company, Profusa focuses on developing next-generation tissue-integrated sensors that enable continuous monitoring of individual biochemical data, providing reliable medical-grade data for personal and medical use.
- Experienced Management: Profusa is led by a seasoned management team and a world-class board of directors, committed to commercializing its long-lasting, injectable, and affordable biosensors, thereby enhancing its competitive position in the market.
- Future Outlook: The company plans to continue executing its compliance strategy and aims to meet other Nasdaq listing requirements to ensure long-term growth and stability in the capital market.
See More
Profusa Securities Transfer to Nasdaq Capital Market Approved
- Listing Transfer Approval: Profusa announced that the Nasdaq Hearings Panel approved its transfer of securities listing from the Nasdaq Global Market to the Nasdaq Capital Market, indicating the company's compliance and operational viability in the capital market.
- Compliance Requirements: The company stated that continued listing on Nasdaq is contingent upon meeting specific interim milestones and adhering to bid price and stockholders' equity requirements by July 6, 2026, ensuring its financial health.
- Significance of Timeline: This decision provides Profusa with additional time and space to achieve necessary financial metrics, thereby mitigating potential delisting risks and enhancing investor confidence.
- Market Strategy Adjustment: The move to the Capital Market not only reflects the company's current market positioning but may also open new opportunities for future financing and growth strategies, particularly against the backdrop of ongoing developments in the digital health sector.
See More
Profusa Secures Nasdaq Market Transfer Approval
- Transfer Approval: On May 6, 2026, Profusa received approval from the Nasdaq Hearings Panel to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market, indicating the company's ongoing presence in the market.
- Compliance Requirements: The company must meet specific interim milestones and bid price and stockholders' equity requirements by July 6, 2026, to maintain its listing on the Capital Market tier, which is crucial for future financing and operations.
- Technological Innovation: Profusa focuses on developing a new generation of tissue-integrated sensors aimed at providing continuous monitoring of individual biochemical data, enhancing the reliability and personalization of medical data, thereby strengthening its competitive position in the market.
- Company Background: As a commercial-stage digital health company, Profusa is led by an experienced management team and a world-class board, dedicated to advancing medical technology through its long-lasting, injectable biosensors.
See More
Profusa Evaluates Strategic Growth Alternatives to Enhance Shareholder Value
- Strategic Evaluation Initiated: Profusa's Board has launched a process to evaluate strategic growth alternatives aimed at maximizing shareholder value through various means such as asset transactions and commercial partnerships, thereby enhancing the company's execution capabilities and long-term growth potential.
- Resource Allocation Optimization: The company is prioritizing resource and capital allocation towards advancing the Lumee Oxygen platform's European CE Mark approval and revenue opportunities in its Healthcare Research business to support near-term execution and value creation.
- Asset Purchase Agreement: On April 21, 2026, Profusa entered into an Asset Purchase Agreement with Bio Insights LLC to acquire substantially all know-how assets related to the PanOmics Assay, which is expected to enhance its competitiveness in the precision medicine sector.
- Regulatory Progress Update: The company has successfully completed two required on-site audits by the European Notified Body GMED and is actively addressing feedback, anticipating CE Mark certification completion in Q3 or early Q4 2026, further advancing its product commercialization efforts.
See More
Profusa Inc. Initiates Evaluation Process for Asset Transactions, Partnerships, Business Combinations, and Other Corporate Agreements
Corporate Evaluation Process: The article discusses the evaluation process for assessing various corporate deals, including asset deals and partnerships.
Types of Deals Covered: It highlights the focus on business combinations and other corporate agreements that are subject to evaluation.
Importance of Evaluation: Emphasizes the significance of thorough evaluations in ensuring successful corporate transactions.
Broader Implications: Suggests that the evaluation process can impact strategic decision-making and overall business performance.
See More
Profusa Submits CE Mark Application for Lumee Oxygen Platform
- CE Mark Progress: Profusa has submitted its response package to GMED for the Lumee Oxygen Platform, marking a significant milestone in the MDR conformity assessment process aimed at obtaining CE Mark certification to support its commercialization strategy in Europe.
- Technical Documentation Updates: The response package includes updates on technical documentation, quality system evidence, and clinical evaluation activities, demonstrating the company's ongoing efforts to meet regulatory requirements, thereby enhancing its competitive position in the market.
- Real-Time Monitoring Capability: The Lumee Oxygen Platform is designed to provide continuous, real-time monitoring of tissue oxygen levels through its proprietary tissue-integrated biosensor technology, addressing clinicians' needs for objective tissue perfusion data that may improve patient monitoring and treatment decision-making.
- Future Outlook: Although the CE Mark review process is ongoing, Profusa is committed to supporting the review and providing updates on significant regulatory milestones, reflecting its confidence in future product launches and keen insight into market demands.
See More
Profusa Inc. Lists on Nasdaq Capital Market to Ensure Compliance
- Listing Progress: Profusa Inc. officially lists on the Nasdaq Capital Market as of May 15, 2026, marking a strategic move to comply with the Nasdaq Hearings Panel's requirements for bid price and stockholders' equity to maintain its listing status.
- Technological Innovation: As a digital health company, Profusa focuses on developing next-generation tissue-integrated sensors that enable continuous monitoring of individual biochemical data, providing reliable medical-grade data for personal and medical use.
- Experienced Management: Profusa is led by a seasoned management team and a world-class board of directors, committed to commercializing its long-lasting, injectable, and affordable biosensors, thereby enhancing its competitive position in the market.
- Future Outlook: The company plans to continue executing its compliance strategy and aims to meet other Nasdaq listing requirements to ensure long-term growth and stability in the capital market.
See More
Profusa Securities Transfer to Nasdaq Capital Market Approved
- Listing Transfer Approval: Profusa announced that the Nasdaq Hearings Panel approved its transfer of securities listing from the Nasdaq Global Market to the Nasdaq Capital Market, indicating the company's compliance and operational viability in the capital market.
- Compliance Requirements: The company stated that continued listing on Nasdaq is contingent upon meeting specific interim milestones and adhering to bid price and stockholders' equity requirements by July 6, 2026, ensuring its financial health.
- Significance of Timeline: This decision provides Profusa with additional time and space to achieve necessary financial metrics, thereby mitigating potential delisting risks and enhancing investor confidence.
- Market Strategy Adjustment: The move to the Capital Market not only reflects the company's current market positioning but may also open new opportunities for future financing and growth strategies, particularly against the backdrop of ongoing developments in the digital health sector.
See More
Profusa Secures Nasdaq Market Transfer Approval
- Transfer Approval: On May 6, 2026, Profusa received approval from the Nasdaq Hearings Panel to transfer its securities from the Nasdaq Global Market to the Nasdaq Capital Market, indicating the company's ongoing presence in the market.
- Compliance Requirements: The company must meet specific interim milestones and bid price and stockholders' equity requirements by July 6, 2026, to maintain its listing on the Capital Market tier, which is crucial for future financing and operations.
- Technological Innovation: Profusa focuses on developing a new generation of tissue-integrated sensors aimed at providing continuous monitoring of individual biochemical data, enhancing the reliability and personalization of medical data, thereby strengthening its competitive position in the market.
- Company Background: As a commercial-stage digital health company, Profusa is led by an experienced management team and a world-class board, dedicated to advancing medical technology through its long-lasting, injectable biosensors.
See More
Profusa Evaluates Strategic Growth Alternatives to Enhance Shareholder Value
- Strategic Evaluation Initiated: Profusa's Board has launched a process to evaluate strategic growth alternatives aimed at maximizing shareholder value through various means such as asset transactions and commercial partnerships, thereby enhancing the company's execution capabilities and long-term growth potential.
- Resource Allocation Optimization: The company is prioritizing resource and capital allocation towards advancing the Lumee Oxygen platform's European CE Mark approval and revenue opportunities in its Healthcare Research business to support near-term execution and value creation.
- Asset Purchase Agreement: On April 21, 2026, Profusa entered into an Asset Purchase Agreement with Bio Insights LLC to acquire substantially all know-how assets related to the PanOmics Assay, which is expected to enhance its competitiveness in the precision medicine sector.
- Regulatory Progress Update: The company has successfully completed two required on-site audits by the European Notified Body GMED and is actively addressing feedback, anticipating CE Mark certification completion in Q3 or early Q4 2026, further advancing its product commercialization efforts.
See More
Profusa Inc. Initiates Evaluation Process for Asset Transactions, Partnerships, Business Combinations, and Other Corporate Agreements
Corporate Evaluation Process: The article discusses the evaluation process for assessing various corporate deals, including asset deals and partnerships.
Types of Deals Covered: It highlights the focus on business combinations and other corporate agreements that are subject to evaluation.
Importance of Evaluation: Emphasizes the significance of thorough evaluations in ensuring successful corporate transactions.
Broader Implications: Suggests that the evaluation process can impact strategic decision-making and overall business performance.
See More
